View abstract

Cet abstract a été assigné à session AOB and FRO E-Posters

Titre	Audit of wet AMD patients treated with IV Ranibizumab over 6-12 months
Abstract Nr.	3028

But	The “Treat and Extend” regimen (TER) was introduced to place the issue of monthly follow-ups, as a new and better approach for individualized patient care. Our study attempts to assess the change of the VA when using the TER.
Méthodes	Between March 2013 and June 2016, 27 patients with neovascular AMD at Western Eye Hospital in London were included in the retrospective study. The inclusion criterion was: exudative AMD treated with Rnibizumab and with a minimal follow up of six months. We excluded patients who had treatment with other anti-VEGF, patients on PRN protocol were excluded from the study as well. Best-corrected visual acuity was collected at each visit and converted into logMAR unit, and CRT was recorded for each visit in which an OCT was used.
Résultats	Twenty seven patients naïve exudatine AMD patients met the inclusion criteria and were recruited in this study Among the treated eyes included in this analysis, 41% experienced a significant VA gain of 15 ETDRS letters or more, 7% had a significant VA loss of 15 ETDRS letters or more and 52% obtained VA stabilization.
Conclusion	Among the treated eyes included in this analysis, 41% experienced a significant VA gain of 15 ETDRS letters or more, 7% had a significant VA loss of 15 ETDRS letters or more and 52% obtained VA stabilization.
Conflit d'intérêt	Oui
Détails conflits d'intérêt	To discuss the effecacy of Ranbizumab Treat & Extend in treating patients with Wet AMD

Auteur 1

Nom	HAMOUD
Initiales	A
Institut	Medical Retina, Western Eye Hospital
Ville	London

Auteur 2

Nom	Younis
Initiales	S
Institut	Medical Retina, Western Eye Hospital
Ville	London